These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15046701)

  • 21. The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD.
    Pacyna JE; Kim S; Yost K; Sedlacek H; Petereit D; Kaur J; Rapkin B; Grubb R; Paskett E; Chang GJ; Sloan J; Basch E; Major B; Novotny P; Taylor J; Buckner J; Parsons JK; Morris M; Tilburt JC
    BMC Cancer; 2018 Aug; 18(1):788. PubMed ID: 30081846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
    Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
    Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.
    Barocas DA; Alvarez J; Resnick MJ; Koyama T; Hoffman KE; Tyson MD; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF
    JAMA; 2017 Mar; 317(11):1126-1140. PubMed ID: 28324093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and pilot evaluation of a personalized decision support intervention for low risk prostate cancer patients.
    Belkora J; Chan JM; Cooperberg MR; Neuhaus J; Stupar L; Weinberg T; Broering JM; Tenggara I; Cowan JE; Rosenfeld S; Kenfield SA; Van Blarigan EL; Simko JP; Witte J; Carroll PR
    Cancer Med; 2020 Jan; 9(1):125-132. PubMed ID: 31714037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?
    Barbosa PV; Thomas IC; Srinivas S; Buyyounouski MK; Chung BI; Chertow GM; Asch SM; Wagner TH; Brooks JD; Leppert JT
    Eur Urol; 2016 Aug; 70(2):227-30. PubMed ID: 26948397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team.
    Fleming C; Wasson JH; Albertsen PC; Barry MJ; Wennberg JE
    JAMA; 1993 May; 269(20):2650-8. PubMed ID: 8487449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A critical review of clinical practice guidelines for the management of clinically localized prostate cancer.
    Dahm P; Yeung LL; Chang SS; Cookson MS
    J Urol; 2008 Aug; 180(2):451-9; discussion 460. PubMed ID: 18550100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How do patients choose between active surveillance, radical prostatectomy, and radiotherapy? The effect of a preference-sensitive decision aid on treatment decision making for localized prostate cancer.
    Lamers RE; Cuypers M; de Vries M; van de Poll-Franse LV; Ruud Bosch JL; Kil PJ
    Urol Oncol; 2017 Feb; 35(2):37.e9-37.e17. PubMed ID: 28341494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate cancer staging: should MR imaging be used?--A decision analytic approach.
    Jager GJ; Severens JL; Thornbury JR; de La Rosette JJ; Ruijs SH; Barentsz JO
    Radiology; 2000 May; 215(2):445-51. PubMed ID: 10796923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient preference-based treatment thresholds and recommendations: a comparison of decision-analytic modeling with the probability-tradeoff technique.
    Man-Son-Hing M; Laupacis A; O'Connor AM; Coyle D; Berquist R; McAlister F
    Med Decis Making; 2000; 20(4):394-403. PubMed ID: 11059472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility evaluations for Markov states of lung cancer for PET-based disease management.
    Papatheofanis FJ
    Q J Nucl Med; 2000 Jun; 44(2):186-90. PubMed ID: 10967627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
    Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M
    Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
    Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
    Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Health economics evaluation of magnetic resonance imaging for the staging of prostate cancer for Austria and Germany].
    Stadlbauer A; Bernt R; Salomonowitz E; Plas E; Strunk G; Eberhardt K
    Rofo; 2012 Jun; 184(6):556-64. PubMed ID: 22473509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer.
    Gore JL; Kwan L; Lee SP; Reiter RE; Litwin MS
    J Natl Cancer Inst; 2009 Jun; 101(12):888-92. PubMed ID: 19509365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.
    Sommers BD; Beard CJ; D'Amico AV; Dahl D; Kaplan I; Richie JP; Zeckhauser RJ
    Cancer; 2007 Nov; 110(10):2210-7. PubMed ID: 17893907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment options for localized prostate cancer: quality-adjusted life years and the effects of lead-time.
    Bhatnagar V; Stewart ST; Bonney WW; Kaplan RM
    Urology; 2004 Jan; 63(1):103-9. PubMed ID: 14751359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013.
    Amin NP; Sher DJ; Konski AA
    Appl Health Econ Health Policy; 2014 Aug; 12(4):391-408. PubMed ID: 25022451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient preferences in prostate cancer: a clinician's guide to understanding health utilities.
    Kramer KM; Bennett CL; Pickard AS; Lyons EA; Wolf MS; McKoy JM; Knight SJ
    Clin Prostate Cancer; 2005 Jun; 4(1):15-23. PubMed ID: 15992457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment decision-making strategies and influences in patients with localized prostate carcinoma.
    Gwede CK; Pow-Sang J; Seigne J; Heysek R; Helal M; Shade K; Cantor A; Jacobsen PB
    Cancer; 2005 Oct; 104(7):1381-90. PubMed ID: 16080181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.